ANACARDIO

AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 entered phase 1b/2a clinical development in heart failure patients in 2023.

Also known as: AnaCardio AB

Primary location: Stockholm Sweden